Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 6/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.46 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 2/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | CIT | O14578 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8330499 | 1.00 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL19559844 | 1.00 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| Bromide SCHEMBL11107160 | 0.98 | SLC7A5 (0.54) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL2715188 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL836565 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL246046 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL1174387 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL2517387 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL4318870 | 0.81 | SLC7A5 (0.56) | SLC7A5LARS1ANPEPRNPEPDNPEP | |
| SCHEMBL10296149 | 0.79 | SLC7A5 (0.54) | SLC7A5LARS1ANPEPRNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1744899-A | Piperidine derivatives as CCR5 antagonists | SMITHKLINE BEECHAM CORP (US) | 2006-03-08 | — | — | CN | claimed |
| US-20250339567-A1 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | UNIV MUENCHEN TECH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-1532134-B1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA SA (FR) | 2008-06-04 | — | — | EP | disclosed |
| CN-1744899-A | Piperidine derivatives as CCR5 antagonists | SMITHKLINE BEECHAM CORP (US) | 2006-03-08 | — | — | CN | disclosed |
| EP-1532134-A1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | Aventis Pharma S.A. (FR) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004007477-A1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | WO | disclosed |
| US-5932696-A | REACTING ALKYLATED DIOL WITH CHLOROMETHYL RESIN FOLLOWED BYREACTION WITH CARBONYLDIIMIDAZOLE, SUBSEQUENT ALKYLATION AND SEQUENTIAL TREATMENT AND ACIDIFICATION | WARNER-LAMBERT COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| US-5869579-A | CHLOROMETHYLATED DIVINYBENZENE-STYRENE RESIN MODIFIED WITH BRANCHED DIOL AND CARBONYLDIIMIDAZOLE; INTERMEDIATES | WARNER-LAMBERT COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0565965-B1 | Benzo b thiophen-5-yl derivative and process for producing the same | TOYAMA CHEMICAL CO LTD (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5380878-A | Benzo[b]thiophen-5-yl derivative and process for producing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
| US-5153274-A | Reacting a carboxylated acrylonitrile-butadiene polymer and the resin product of a diamine or dihydrazide and an N,N'-bisimide of an unsaturated carboxylic acid; adhesives; composites; toughness | THE SECRETARY OF STATE FOR DEFENCE IN HER MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1992-10-06 | — | — | US | disclosed |
| US-5087681-A | Thermosetting composition; crosslinked polyimide matrix | SECRETARY OF STATE FOR DEFENCE IN HER MAJESTY'S GOVERNMENT OF UNITED KINGDOM (GB) | 1992-02-11 | — | — | US | disclosed |
| EP-0165812-B1 | THERMOSETTING IMIDE RESIN COMPOSITIONS | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1988-11-09 | — | — | EP | disclosed |
| EP-0131027-B1 | CURABLE THERMOSETTING PREPOLYMERISED IMIDE RESIN COMPOSITIONS | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1986-12-17 | — | — | EP | disclosed |
| EP-0165812-A2 | Thermosetting imide resin compositions | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1985-12-27 | — | — | EP | disclosed |
| EP-0131027-A1 | CURABLE THERMOSETTING PREPOLYMERISED IMIDE RESIN COMPOSITIONS. | SECR DEFENCE BRIT (GB) | 1985-01-16 | — | — | EP | disclosed |
| US-4459227-A | Para-hydroxyphenylhydrazines as in situ precursors of iminoquinones and quinones | DUKE UNIVERSITY (US) | 1984-07-10 | — | — | US | disclosed |
| WO-1984002528-A1 | CURABLE THERMOSETTING PREPOLYMERISED IMIDE RESIN COMPOSITIONS | SECR DEFENCE BRIT (GB) | 1984-07-05 | — | — | WO | disclosed |
| US-4438249-A | Biodegradable polyurethane urea acyl semicarbazides for the manufacture of biodegradable alloimplants | LIPATOVA TATYANA E (SU) | 1984-03-20 | — | — | US | disclosed |
| US-4211861-A | N,N*-BISIMIDE | TECHNOCHEMIE GMBH VERFAHRENSTECHNIK (DE) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339567-A1 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | RXFP2, XPNPEP2, ANTXR2 | SLC7A5 484/4885LARS1 1324/4885ANPEP 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.